Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles


90Yttrium Microsphere Radioembolization for Liver Malignancies: A Technical Overview

Sandeep T Laroia

Citation Information : Laroia ST. 90Yttrium Microsphere Radioembolization for Liver Malignancies: A Technical Overview. J Postgrad Med Edu Res 2013; 47 (1):61-64.

DOI: 10.5005/jp-journals-10028-1057

Published Online: 01-03-2013

Copyright Statement:  Copyright © 2013; The Author(s).


How to cite this article

Laroia ST. 90Yttrium Microsphere Radioembolization for Liver Malignancies: A Technical Overview. J Postgrad Med Edu Res 2013;47(1):61-64.

PDF Share
  1. Atlanta: American Cancer Society 2004.
  2. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2004;7:431-41.
  3. Recent advances in the pharmacological treatment of colorectal cancer. Expert Opin Investig Drugs 2003;12:423-34.
  4. Surgical treatment of liver metastases. Semin Oncol 2002;29:107-18.
  5. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124-29.
  6. Imaging diagnosis of hepatocellular carcinoma with differentiation from other pathology. Clin Liver Dis 2005;9:253-79.
  7. Detection of hepatocellular carcinoma: Value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 2002;179:67-73.
  8. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): Diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004;18: 1089-104.
  9. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC and JIS) in Japan. Am J Gastroenterol 2005;100:1764-71.
  10. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients. Cancer 1985;56:918-28.
  11. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003;3:8-24.
  12. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005;103:1856-64.
  13. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005;16:911-35.
  14. Multi-institutional comparison of 99mTc-MAA lung shunt fraction for transcatheter Y-90 radioembolization. New Orleans, LA: Presented at the Annual Meeting of the Society of Interventional Radiology, 2005.
  15. Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies. J Am Pharm Assoc (Wash) 2000;40:46-51.
  16. Yttrium-90 microsphere therapy for hepatic malignancy: Devices, indications, technical considerations and potential complications. Radiographics 2005;25(suppl 1):S41-S55.
  17. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (Thera Sphere): Assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;9:522-29.
  18. Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. J Gastroenterol Hepatol 2004;19:347-49.
  19. Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: Trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med 2004;3:49-56.
  20. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 2011 Jun;22(6):780-86.
  21. Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction. J Vasc Interv Radiol 2010 Aug;21(8):1213-18.
  22. Proximal arterio portal shunting associated with hepatocellular carcinoma: Features revealed by dynamic helical CT. AJR 1999;172:403-07.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.